standards > reporting guideline > DOI:10.25504/FAIRsharing.4z037c
FAIRsharing is now available for record creation, update, and search at, please visit us there! Replacement of this read-only version of the legacy site with the new version of FAIRsharing is planned for early January 2022.

ready LINCS Extended Metadata Standard: Antibody Reagents

Abbreviation: LINCS 2: Antibody Reagents

General Information
LINCS Production Phase 2 Extended Metadata Standards were developed by the LINCS consortium with the goal of generating an integrated view across the diverse LINCS data resources. These guidelines are focused on the minimum required information to model LINCS assays and results and have been recommended by LINCS for adoption beyond the LINCS project. Antibodies are extremely useful because of their high target specificity in detection of proteins, capture of proteins for isolation, purification and quantification, and selective inhibition of protein function (e.g., membrane receptor). Important metadata to be reported include a standardized name and ID of the antibody, identity of the target protein, target organism, information on the immunogen (name, source, modification of the protein/peptide), antibody clonality, antibody isotype, antibody purity, antibody specificity, and whether it was used as a primary or secondary antibody in an assay.

This record replaces or incorporates the following deprecated resources:


Countries that developed this resource United States

Created in 2015

Taxonomic range


How to cite this record LINCS 2: Antibody Reagents; LINCS Extended Metadata Standard: Antibody Reagents; DOI:; Last edited: Jan. 8, 2019, 1:27 p.m.; Last accessed: Dec 07 2021 9:35 p.m.

This record is maintained by cchung  ORCID

Record added: April 27, 2016, 2:15 p.m.
Record updated: Oct. 22, 2016, 7:50 p.m. by The FAIRsharing Team.

Show edit history



Additional Information


    No tools defined


No XSD schemas defined

Access / Retrieve Data

Conditions of Use


Metadata Standard and Data Exchange Specifications to Describe, Model, and Integrate Complex and Diverse High-Throughput Screening Data from the Library of Integrated Network-based Cellular Signatures (LINCS).

Vempati UD,Chung C,Mader C,Koleti A,Datar N,Vidovic D,Wrobel D,Erickson S,Muhlich JL,Berriz G,Benes CH,Subramanian A,Pillai A,Shamu CE,Schurer SC
J Biomol Screen 2014

View Paper (PubMed) View Publication

Related Databases (1)
Library of Integrated Network-Based Cellular Signatures Data Portal
The LINCS Data Portal provides a unified interface for searching LINCS dataset packages and reagents. LINCS data are being made openly available as a community resource through a series of data releases, so as to enable scientists to address a broad range of basic research questions and to facilitate the identification of biological targets for new disease therapies. LINCS datasets consist of assay results from cultured and primary human cells treated with bioactive small molecules, ligands such as growth factors and cytokines, or genetic perturbations. Many different assays are used to monitor cell responses, including assays measuring transcript and protein expression; cell phenotype data are captured by biochemical and imaging readouts. Assays are typically carried out on multiple cell types, and at multiple timepoints; perturbagen activity is monitored at multiple doses.

Implementing Policies

This record is not implemented by any policy.


Record Maintainer